|C-11 Kristin Karlsson
Regulatory pharmacometrics in the EU in practice and the role of the Modelling and Simulation Working Group
|C-12 Anna Nordmark
The new draft EMA Guidance on PBPK – The qualification of the intended use concept
|D-03 Miro Eigenmann
Therapeutic antibody concentrations at the biophase
|D-08 Salvatore D'Agate
Model-based screening of compounds for the treatment of Chagas disease, a neglected tropical disease.